These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 1397699)

  • 1. Lp(a) concentrations in NIDDM.
    Haffner SM; Morales PA; Stern MP; Gruber MK
    Diabetes; 1992 Oct; 41(10):1267-72. PubMed ID: 1397699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum lipids and lipoprotein(a) concentrations in Chinese NIDDM patients. Relation to metabolic control.
    Chang CJ; Kao JT; Wu TJ; Lu FH; Tai TY
    Diabetes Care; 1995 Aug; 18(8):1191-4. PubMed ID: 7587858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of NIDDM on lipoprotein(a) concentration and apolipoprotein(a) size.
    Rainwater DL; MacCluer JW; Stern MP; VandeBerg JL; Haffner SM
    Diabetes; 1994 Jul; 43(7):942-6. PubMed ID: 8013760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics of type II diabetic subjects consuming high versus low carbohydrate diets in Mexico City and San Antonio, Texas.
    Gonzélez C; Stern MP; Mitchell BD; Valdez RA; Haffner SM; Pérez BA
    Diabetes Care; 1994 May; 17(5):397-404. PubMed ID: 8062606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipids and Lp(a) lipoprotein levels and coronary artery disease in subjects with non-insulin-dependent diabetes mellitus.
    O'Brien T; Nguyen TT; Harrison JM; Bailey KR; Dyck PJ; Kottke BA
    Mayo Clin Proc; 1994 May; 69(5):430-5. PubMed ID: 8170193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasminogen activator inhibitor (PAI-1) activity is elevated in Asian and Caucasian subjects with non-insulin-dependent (type 2) diabetes but not in those with impaired glucose tolerance (IGT) or non-diabetic Asians.
    Nagi DK; Mohamed Ali V; Jain SK; Walji S; Yudkin JS
    Diabet Med; 1996 Jan; 13(1):59-64. PubMed ID: 8741814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma lipoprotein (a) levels in Turkish NIDDM patients with and without vascular diabetic complications.
    Erem C; Değer O; Bostan M; Orem A; Sönmez M; Ulusoy S; Telatar M
    Acta Cardiol; 1999 Aug; 54(4):203-7. PubMed ID: 10511896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of insulin treatment on serum lipoprotein(a) in non-insulin-dependent diabetes.
    Kuusi T; Yki-Järvinen H; Kauppinen-Mäkelin R; Jauhiainen M; Ehnholm C; Kauppila M; Seppälä P; Viikari J; Kujansuu E; Rajala S
    Eur J Clin Invest; 1995 Mar; 25(3):194-200. PubMed ID: 7781667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma oxidizability in subjects with normal glucose tolerance, impaired glucose tolerance, and NIDDM.
    Haffner SM; Agil A; Mykkanen L; Stern MP; Jialal I
    Diabetes Care; 1995 May; 18(5):646-53. PubMed ID: 8586002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum lipoprotein (a) concentrations in a population of 819 non-insulin-dependent diabetic patients.
    Durlach V; Gillery P; Bertin E; Taupin JM; Grulet H; Gross A; Leutenegger M
    Diabetes Metab; 1996 Oct; 22(5):319-23. PubMed ID: 8896993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipoprotein(a) in diabetic patients and normoglycemic relatives in familial NIDDM.
    Velho G; Erlich D; Turpin E; Néel D; Cohen D; Froguel P; Passa P
    Diabetes Care; 1993 May; 16(5):742-7. PubMed ID: 8495614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum lipoprotein(a) concentrations and apolipoprotein(a) phenotypes in the families of NIDDM patients.
    Hirata K; Saku K; Jimi S; Kikuchi S; Hamaguchi H; Arakawa K
    Diabetologia; 1995 Dec; 38(12):1434-42. PubMed ID: 8786017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral atherosclerosis and serum lipoprotein(a) in diabetes.
    Wollesen F; Dahlén G; Berglund L; Berne C
    Diabetes Care; 1999 Jan; 22(1):93-8. PubMed ID: 10333909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Greater effect of diabetes on LDL size in women than in men.
    Haffner SM; Mykkänen L; Stern MP; Paidi M; Howard BV
    Diabetes Care; 1994 Oct; 17(10):1164-71. PubMed ID: 7821137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipoprotein(a) in diabetic patients with and without chronic renal failure.
    Guillausseau PJ; Peynet J; Chanson P; Legrand A; Altman JJ; Poupon J; N'Guyen M; Rousselet F; Lubetzki J
    Diabetes Care; 1992 Aug; 15(8):976-9. PubMed ID: 1387074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relatively more atherogenic coronary heart disease risk factors in prediabetic women than in prediabetic men.
    Haffner SM; Miettinen H; Stern MP
    Diabetologia; 1997 Jun; 40(6):711-7. PubMed ID: 9222652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of replacing saturated fat with complex carbohydrate in diets of subjects with NIDDM.
    Abbott WG; Boyce VL; Grundy SM; Howard BV
    Diabetes Care; 1989 Feb; 12(2):102-7. PubMed ID: 2702893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipoprotein(a) in android obesity and NIDDM.
    Wassef N; Sidhom G; Zakareya el-K ; Mohamed el-K
    Diabetes Care; 1997 Nov; 20(11):1693-6. PubMed ID: 9353610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipoprotein (a) levels in African-Americans with NIDDM.
    Scheer WD; Boudreau DA; Cook CB
    Diabetes Care; 1996 Oct; 19(10):1129-34. PubMed ID: 8886562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alteration of lipoprotein(a) concentration with glycemic control in non-insulin-dependent diabetic subjects without diabetic complications.
    Nakata H; Horita K; Eto M
    Metabolism; 1993 Oct; 42(10):1323-6. PubMed ID: 8412745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.